MESTO LERKANIDIPINA V LEChENII ARTERIAL'NOY GIPERTENZII: OSOBENNOSTI KLINIChESKOGO PRIMENENIYa I PERENOSIMOSTI


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review summarizes data on the effectiveness of lercanidipine. Lercanidipine is third-generation dihydropyridine calcium channel blocker, characterized by high vasoselectivity, long duration of action and a good antihypertensive efficacy. High lipophilicity of drug provides gradual and prolonged hypotensive effect of the drug. This reduces the risk of adverse side effects against the background of treatment with lercanidipine and increases compliance to the treatment with this drug. The review summarizes data on the hypotensive efficacy of lercanidipine and its organoprotective properties. The comparison of its efficacy with that of other groups of drugs is presented. The potentials for the use of this drug in elderly patients with arterial hypertension are discussed.

Full Text

Restricted Access

About the authors

L. O Minushkina

References

  1. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascularevents: results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527-35.
  2. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов) // Системные гипертензии 2010. № 3. С. 5-27.
  3. Alvarez C, Gomez E, Simon M, et al. Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake. Eur J Clin Pharmacol 2012;68(7):1043-47.
  4. Zanidip. Summary of product characteristics. Napp Pharmaceuticals Ltd, 2002.
  5. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003;63:2449-72.
  6. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin investig Drugs 1999;8(7): 1043-62.
  7. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2,5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16:1831 -38.
  8. Ciro A. Active dose findings for lercanidipine in a doubleblind, placebo-controlled design in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1997; 29(Suppl. 2):21-5.
  9. Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. int J Clin Pract 2006;60( 11):1364-70.
  10. Romito R, Pansini Mi, Perticone F, et al. Comparative effect of lercanidipine, felodipine, and nifedipine GiTS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003;5(4):249-53.
  11. James iG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16(8):605-10.
  12. Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebocontrolled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;21(12): 917-24.
  13. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000;60(5):1123-40.
  14. Poncelet P, Ribstein J, Goullard L, et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study Ann Cardiol Angeiol (Paris). 2004;53(3):123-30.
  15. Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997;29:40-4.
  16. Millar-Craig M, Shaffu B, Greenough A, et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003; 17(11 ):799-806.
  17. Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr. 2003;37(3): 203-12.
  18. Tisaire-Sonchez J, Roma J, Camacho-Azcargorta i, et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc Health Risk Manag 2006;2(4):491-98.
  19. Luque M, Navarro A, Martell N. Use of NonSteroidal Anti-inflammatory Drugs Does Not Modify the Antihypertensive Effect of Lercanidipine in Essential Hypertension Br J Cardiol 2006;13(5):353-59.
  20. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DiAL study (diabete, ipertensione, albuminuria, lercanidipi-na). Diabetes Nutr Metab 2004;17(5):259-66.
  21. Robles NR, Romero B, de Vinuesa EG. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010;32(2):192-97.
  22. Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;27(1):73-80.
  23. Topal C, Erkoc R, Sayarlioglu H. Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients. Ren Fail 2009;31 (6):446-51.
  24. Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003;41(4):950-55.
  25. Grassi G, Quarti-Trevano F, Scopelliti F, et al. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Press 2006;15(5):268-74.
  26. Mackenzie iS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009;54(2):409-13.
  27. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007;3:999-1005.
  28. Milani G, Ragazzi M, Simonetti GD, et al. Superior palatability of crushed lercanidipine compared with amlodipine among children. Br J Clin Pharmacol 2010;69(2):204-6.
  29. Hollenberg NK. Observations on the safety of lercanidipine: adverse event data from placebocontrolled trials. Am J Hypertens 2002; 15:58-9.
  30. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 2009;31 (8): 1652-63.
  31. Chia YC, Yeoh ES, Ng CJ, et al. Efficacy and tolerability of lercanidipine in mild to moderate hypertension among Asians of different ethnic groups. Singapore Med J 2009; 50(5):500-55.
  32. Barrios V, Escobar C, de la Figuera M, et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc Ther 2008;26(1):2-9.
  33. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Study group of the regional Unit of the italian Society of Hypertension. improved Tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003;(Suppl. 1 ): 14-21.
  34. Burnier M, Gasser UE. Effi cacy and tolerability of lercanidipine in patients with hypertension: results of a Phase iV study in general practice. Expert Opin Pharmacother 2007;8:2215-23.
  35. Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GiTS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003 Jul; 16(7):596-959.
  36. Cicero AF, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012;34(2):113-17.
  37. Cleophas TJ, van Ouwerkerk BM, van der Meulen J, Zwinderman AH. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies. Angiology 2001;52:469-75.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies